These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 29986988)

  • 1. New Immunotherapies in Oncology Treatment and Their Side Effect Profiles.
    Sriratana P; Norton J
    J Am Board Fam Med; 2018; 31(4):620-627. PubMed ID: 29986988
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Current developments in immunotherapy in the treatment of multiple myeloma.
    Köhler M; Greil C; Hudecek M; Lonial S; Raje N; Wäsch R; Engelhardt M
    Cancer; 2018 May; 124(10):2075-2085. PubMed ID: 29409124
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Immunotherapy: enhancing the efficacy of this promising therapeutic in multiple cancers.
    Inthagard J; Edwards J; Roseweir AK
    Clin Sci (Lond); 2019 Jan; 133(2):181-193. PubMed ID: 30659159
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immunogenicity of immunomodulatory, antibody-based, oncology therapeutics.
    Davda J; Declerck P; Hu-Lieskovan S; Hickling TP; Jacobs IA; Chou J; Salek-Ardakani S; Kraynov E
    J Immunother Cancer; 2019 Apr; 7(1):105. PubMed ID: 30992085
    [TBL] [Abstract][Full Text] [Related]  

  • 5. New NCCN Guidelines: Recognition and Management of Immunotherapy-Related Toxicity.
    Thompson JA
    J Natl Compr Canc Netw; 2018 May; 16(5S):594-596. PubMed ID: 29784734
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Immunotherapy for the Treatment of Hodgkin Lymphoma: An Evolving Paradigm.
    Bair SM; Mato A; Svoboda J
    Clin Lymphoma Myeloma Leuk; 2018 Jun; 18(6):380-391. PubMed ID: 29685424
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Inflammatory and Infectious Syndromes Associated With Cancer Immunotherapies.
    Fishman JA; Hogan JI; Maus MV
    Clin Infect Dis; 2019 Aug; 69(6):909-920. PubMed ID: 30520987
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine dysfunction induced by immune checkpoint inhibitors: Practical recommendations for diagnosis and clinical management.
    Barroso-Sousa R; Ott PA; Hodi FS; Kaiser UB; Tolaney SM; Min L
    Cancer; 2018 Mar; 124(6):1111-1121. PubMed ID: 29313945
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chimeric Antigen Receptor T Cell Therapy in Hematology.
    Ataca P; Arslan Ö
    Turk J Haematol; 2015 Dec; 32(4):285-94. PubMed ID: 26377367
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis and Management of Immune Related Adverse Events (irAEs) in Cancer Immunotherapy.
    Liu YH; Zang XY; Wang JC; Huang SS; Xu J; Zhang P
    Biomed Pharmacother; 2019 Dec; 120():109437. PubMed ID: 31590992
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Immunotherapies of cancer: Is there any impact on patient cognitive functions?].
    Castel H; Joly F
    Med Sci (Paris); 2020; 36(8-9):695-699. PubMed ID: 32821042
    [No Abstract]   [Full Text] [Related]  

  • 12. [Not Available].
    Feuchtinger T
    Drug Res (Stuttg); 2018 Nov; 68(S 01):S12-S13. PubMed ID: 30453365
    [No Abstract]   [Full Text] [Related]  

  • 13. The current landscape of early drug development for patients with sarcoma in the immunotherapy era.
    Sebio A; Wilky BA; Keedy VL; Jones RL
    Future Oncol; 2018 May; 14(12):1197-1211. PubMed ID: 29699407
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Immunotherapy with Checkpoint Blockade in the Treatment of Urothelial Carcinoma.
    Siefker-Radtke AO; Apolo AB; Bivalacqua TJ; Spiess PE; Black PC
    J Urol; 2018 May; 199(5):1129-1142. PubMed ID: 29113841
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Oncologic Emergencies: Immune-Based Cancer Therapies and Complications.
    Long B; Brém E; Koyfman A
    West J Emerg Med; 2020 Apr; 21(3):566-580. PubMed ID: 32421502
    [TBL] [Abstract][Full Text] [Related]  

  • 16. From a Patient Advocate's Perspective: Does Cancer Immunotherapy Represent a Paradigm Shift?
    Madden DL
    Curr Oncol Rep; 2018 Feb; 20(1):8. PubMed ID: 29411148
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging role of immunotherapy in urothelial carcinoma-Future directions and novel therapies.
    Park JC; Hahn NM
    Urol Oncol; 2016 Dec; 34(12):566-576. PubMed ID: 27773553
    [TBL] [Abstract][Full Text] [Related]  

  • 18. NK cell-based immunotherapy for cancer.
    Fang F; Xiao W; Tian Z
    Semin Immunol; 2017 Jun; 31():37-54. PubMed ID: 28838796
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Clinical development of immunotherapy for prostate cancer.
    Noguchi M; Koga N; Igawa T; Itoh K
    Int J Urol; 2017 Sep; 24(9):675-680. PubMed ID: 28636142
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunotherapies: Exploiting the Immune System for Cancer Treatment.
    Koury J; Lucero M; Cato C; Chang L; Geiger J; Henry D; Hernandez J; Hung F; Kaur P; Teskey G; Tran A
    J Immunol Res; 2018; 2018():9585614. PubMed ID: 29725606
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.